Your Cart is Empty
BUY 1 GET 1 FREE · AUTO APPLIES AT CHECKOUT
Few botanical substances have generated as much regulatory debate in recent American history as kratom. The question of whether to ban kratom — or regulate it — has played out in federal agencies, state legislatures, scientific journals, and public forums over the past decade. Understanding where this debate stands is essential for consumers, retailers, and anyone with a stake in herbal wellness freedom and public health.
Kratom has existed in a federal legal gray zone for most of its American history. It is not a controlled substance under the Controlled Substances Act (CSA), meaning it can be legally bought and sold at the federal level. However, the FDA has never approved kratom as a dietary supplement, food ingredient, or medicine — placing it outside regulatory frameworks that typically govern safety and quality standards.
The FDA has issued numerous warning letters to kratom vendors making unsubstantiated medical claims, and has seized kratom shipments under import alerts citing concerns about adulteration and misbranding.
In August 2016, the DEA announced it would use emergency scheduling authority to temporarily place kratom's two primary alkaloids — mitragynine and 7-hydroxymitragynine — into Schedule I of the CSA, alongside heroin and LSD.
The announcement triggered an unprecedented public response. Over 140,000 comments opposed the scheduling. A bipartisan group of 51 members of Congress wrote to the DEA urging reconsideration. Researchers raised concerns that scheduling would eliminate kratom as a potential research subject for opioid addiction treatment. The DEA withdrew the notice in October 2016 — a rare reversal highlighting the political and scientific complexity of the kratom debate.
The FDA has maintained a strongly skeptical stance toward kratom, characterizing it as an opioid with significant abuse potential. Key FDA actions include:
States That Have Banned or Restricted Kratom
As of 2024, kratom is banned or significantly restricted in the following states:
Additionally, several cities and counties in otherwise kratom-legal states have enacted local bans. See our complete guide:Is Kratom Legal?
Rather than pursuing outright bans, a growing number of states have passed versions of the Kratom Consumer Protection Act — model legislation developed by the American Kratom Association (AKA) that establishes:
States that have passed KCPA-style legislation as of 2024 include Utah, Georgia, Arizona, Oklahoma, and Nevada. This regulatory approach — treating kratom as a regulated consumer product rather than a controlled substance — is increasingly seen as a pragmatic middle ground.
The American Kratom Association and a broad coalition of consumers, researchers, and harm reduction advocates argue that kratom provides meaningful relief for pain patients and those managing opioid withdrawal, and that prohibition drives users toward more dangerous and unregulated alternatives.
The FDA, some addiction medicine specialists, and some public health advocates argue that kratom's opioid receptor activity, dependence potential, and reported fatalities make it a public health risk requiring tighter controls.
Kratom remains federally legal but unregulated at the national level. Six states have enacted full bans. Many more states regulate it through KCPA or similar frameworks. The regulatory landscape continues to evolve — consumers should verify current laws in their specific state and locality before purchasing.
No — not at the federal level. Kratom is not scheduled under the Controlled Substances Act. In some states (Alabama, Arkansas, Indiana, Rhode Island, Vermont, Wisconsin), it is classified as a controlled substance under state law.
The FDA cannot unilaterally ban kratom as a botanical product, but it can recommend scheduling to the DEA, restrict imports, and take enforcement actions against mislabeled products. A formal scheduling action through the DEA would require a more extensive regulatory process.
The kratom regulation debate is far from settled. The KCPA model represents a promising path forward — ensuring product safety and age restrictions while preserving adult consumer access.PureCraft CBD supports responsible kratom regulation and provides fully transparent, lab-tested products.
⚠ Important | Ehlers-Danlos syndrome is a complex connective tissue disorder requiring specialist management. CBD is not a treatment for EDS. Disc...
Read More
⚠ Important | Binge eating disorder is a serious psychiatric condition requiring clinical evaluation and evidence-based treatment — typically cogn...
Read More
⚠ Important | Secondary Raynaud's phenomenon is associated with underlying conditions (scleroderma, lupus, rheumatoid arthritis) that require phys...
Read More